A short clip weighing the two most common GLP-1 drugs against each other. It is a general explainer, so watch for his reasoning.
Recap by typeshit. Post by @realdrbae on Instagram.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
Polskie Radio reports the FDA has added a new warning to the labels of weight loss drugs, Wegovy among them. Details are at the link.
The News & Observer shares a look at how researchers are redesigning peptides so they can work as pills instead of injections.
Loading…